Education
About Us
Working with TipRanks
Follow Us
Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
2395 Stock Chart & Stats
¥1622.00
¥20.00(1.21%)
At close: 4:00 PM EST
¥1622.00
¥20.00(1.21%)
Day’s Range― - ―
52-Week Range¥1,142.00 - ¥2,005.00
Previous CloseN/A
Volume203.40K
Average Volume (3M)231.41K
Market Cap
¥69.77B
Enterprise Value¥96.85B
Total Cash (Recent Filing)¥11.57B
Total Debt (Recent Filing)¥36.58B
Price to Earnings (P/E)17.5
Beta0.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.79%
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)1.49
Price to Sales (P/S)1.84
P/FCF Ratio-15.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,400.00Price Target Upside109.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Outsourced R&D / CRO Business ModelA diversified CRO model serving preclinical, clinical and laboratory-animal needs creates durable demand from pharma/biotech outsourcing. Long project timelines and regulatory-driven work produce sticky contracted revenue and high customer switching costs that support steady mid-term growth.
High Gross Profit MarginsConsistently >50% gross margins indicate structural pricing power and efficient cost control in lab services. High gross margins provide room to absorb SG&A and R&D, fund investments in specialized capabilities, and sustain profitability even if top-line growth moderates over the next several quarters.
Robust Operating Cash ConversionHealthy conversion of accounting profits into operating cash gives financial flexibility to fund operations and working capital without immediate reliance on external capital. This supports execution of multi-period study pipelines and helps stabilize operations while managing capex cycles.
Bears Say
Rising LeverageIncreasing debt levels reduce financial flexibility and raise interest and covenant risk, limiting the company's ability to invest in new facilities or absorb demand shocks. In a capital-intensive service business, higher leverage makes funding future expansion or R&D more costly and riskier.
Negative Free Cash Flow TrendPersistent negative free cash flow requires either higher borrowing or equity funding to sustain growth and capex. Over the medium term this can pressure balance sheet strength, constrain discretionary investments, and amplify the impact of rising leverage on credit metrics and strategic flexibility.
Declining Net And Operating MarginsWorsening net and slight EBIT margin declines signal pressure on operational efficiency or higher SG&A/costs. Combined with EPS contraction noted in fundamentals (EPS growth negative), this reduces retained earnings and the firm’s ability to self-fund growth, weakening resilience over the next several quarters.
Shin Nippon Biomedical Laboratories, Ltd. News
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
Shin Nippon Biomedical Laboratories, Ltd. lowest stock price was ¥1142.00 and its highest was ¥2005.00 in the past 12 months.
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
Shin Nippon Biomedical Laboratories, Ltd.’s market cap is ¥69.77B.
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Currently, no data Available
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
According to Wall Street analysts Shin Nippon Biomedical Laboratories, Ltd.’s price is currently Undervalued.
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
Shin Nippon Biomedical Laboratories, Ltd. pays a Semiannually dividend of ¥30 which represents an annual dividend yield of 2.79%. See more information on Shin Nippon Biomedical Laboratories, Ltd. dividends here
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding.
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
Currently, no hedge funds are holding shares in JP:2395
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
2395 Stock 12 Month Forecast
Average Price Target
¥3,400.00
▲(109.62% Upside)
Technical Analysis
BML
―
Linical Co., Ltd.
―
Eiken Chemical Co., Ltd.
―
Takara Bio Inc.
―
Sapporo Clinical Laboratory Center, Inc.
―
Options Prices
Currently, No data available
---